Humacyte Inc Cash Flow Conversion Efficiency
Humacyte Inc cash flow conversion efficiency. Based on the latest financial reports, Humacyte Inc (HUMA) has a cash flow conversion efficiency ratio of -8.403x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.12 Million) by net assets ($3.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Humacyte Inc (2019–2025)
Cash flow conversion efficiency of Humacyte Inc from 2019 to 2025. This chart illustrates how Humacyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HUMA share price today for real-time trading data and today's change.
Humacyte Inc Cash Flow Conversion Ratio Explained
Humacyte Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Humacyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humacyte Inc ranked by their cash flow conversion efficiency. Also see market cap of Humacyte Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Betr Entertainment Ltd
AU:BBT
|
-0.135x |
|
Red Star Macalline Group Corporation Ltd
F:3S5
|
-0.008x |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
0.117x |
|
Western Bulk Chartering AS
OL:WEST
|
0.075x |
|
Miwon Holdings Co. Ltd
KO:107590
|
0.012x |
|
Eaton Vance Senior Income Closed Fund
NYSE:EVF
|
0.033x |
|
Chung Fu Tex-International Corp
TW:1435
|
-0.010x |
|
Toma as
PR:TOMA
|
N/A |
Annual Cash Flow Conversion Efficiency for Humacyte Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Humacyte Inc from 2019 to 2025. Review HUMA FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.11 Million | $-105.04 Million | -33.786x | -1913.56% |
| 2024-12-31 | $-52.67 Million | $-98.12 Million | 1.863x | +134.43% |
| 2023-12-31 | $13.55 Million | $-73.31 Million | -5.412x | -789.60% |
| 2022-12-31 | $116.93 Million | $-71.13 Million | -0.608x | +8.46% |
| 2021-12-31 | $122.17 Million | $-81.19 Million | -0.665x | +15.48% |
| 2020-12-31 | $70.67 Million | $-55.57 Million | -0.786x | -44.80% |
| 2019-12-31 | $132.20 Million | $-71.79 Million | -0.543x | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more